{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:16:42Z","timestamp":1792786602871,"version":"4.5.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"PhRMA Foundation Predoctoral Fellowship","id":[{"id":"https:\/\/ror.org\/029sjzg14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000008","name":"David and Lucile Packard Foundation","doi-asserted-by":"publisher","award":["2013\u201339274"],"award-info":[{"award-number":["2013\u201339274"]}],"id":[{"id":"10.13039\/100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21EB017938"],"award-info":[{"award-number":["R21EB017938"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"UNC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Carolina Center for Cancer Nanotechnology Excellence","award":["U54CA151652"],"award-info":[{"award-number":["U54CA151652"]}]},{"name":"Eshelman School of Pharmacy"},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jconrel.2015.09.040","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T19:52:58Z","timestamp":1443210778000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"PB","title":["Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery"],"prefix":"10.1016","volume":"220","author":[{"given":"Qi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"McCallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.09.040_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2012.09.038","article-title":"Cancer nanomedicines: so many papers and so few drugs!","volume":"65","author":"Venditto","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2015.06.008","article-title":"The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation","volume":"211","author":"Stapleton","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0025","first-page":"3352","article-title":"Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1758834013517414","article-title":"Tumor heterogeneity in the clinic: is it a real problem?","volume":"6","author":"Janku","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0045","series-title":"Minimal residual disease in cancer therapy \u2014 small things make all the difference","author":"Blatter","year":"2015"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004142","article-title":"Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy","volume":"11","author":"Fu","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0055","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0060","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/nnm.13.191","article-title":"Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles","volume":"9","author":"Toy","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-824X-3-3","article-title":"Nanotechnology-mediated targeting of tumor angiogenesis","volume":"3","author":"Banerjee","year":"2011","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nantod.2010.03.003","article-title":"Targeted nanodelivery of drugs and diagnostics","volume":"5","author":"Phillips","year":"2010","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","article-title":"Passive and active drug targeting: drug delivery to tumors as an example","author":"Torchilin","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0095","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/mp2005615","article-title":"Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery","volume":"9","author":"Amoozgar","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1023\/A:1011930127562","article-title":"Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate)","volume":"15","author":"Passirani","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0168-3659(01)00368-6","article-title":"Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats","volume":"75","author":"Takeuchi","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0110","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/jps.2600840904","article-title":"New synthetic amphiphilic polymers for steric protection of liposomes in vivo","volume":"84","author":"Torchilin","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0115","doi-asserted-by":"crossref","first-page":"11625","DOI":"10.1021\/la302433a","article-title":"Superhydrophilic zwitterionic polymers stabilize liposomes","volume":"28","author":"Cao","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0120","doi-asserted-by":"crossref","first-page":"374252","DOI":"10.1155\/2013\/374252","article-title":"Stealth properties to improve therapeutic efficacy of drug nanocarriers","volume":"2013","author":"Salmaso","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/js9504043","article-title":"Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes","volume":"85","author":"Zalipsky","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kopecek","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2012.11.009","article-title":"Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester","volume":"165","author":"J\u00e4ger","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0145","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1039\/b900456d","article-title":"Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution","volume":"19","author":"Choi","year":"2009","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0155","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F","article-title":"Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium","volume":"54","author":"Konno","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0160","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.bjc.6600343","article-title":"Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis","volume":"86","author":"Fenton","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0165","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1593\/neo.12858","article-title":"Localized hypoxia results in spatially heterogeneous metabolic signatures in breast tumor models","volume":"14","author":"Jiang","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2015.04.006","article-title":"Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model","volume":"207","author":"Ekdawi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jconrel.2013.08.296","article-title":"Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes","volume":"172","author":"Stapleton","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0180","first-page":"1","article-title":"Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect","author":"Huynh","year":"2015","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0185","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0190","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","article-title":"Cancer active targeting by nanoparticles: a comprehensive review of literature","volume":"141","author":"Bazak","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0195","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/nn4018922","article-title":"Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands","volume":"7","author":"Fiandra","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0200","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1021\/mp400315p","article-title":"Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts","volume":"10","author":"Hoang","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2014.05.041","article-title":"MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery","volume":"473","author":"Sayari","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2015.01.042","article-title":"Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer","volume":"360","author":"Shen","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0215","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1023\/A:1019885807067","article-title":"The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells","volume":"19","author":"David","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0220","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3109\/13880209.2013.874533","article-title":"Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy","volume":"52","author":"Wu","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0225","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0230","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.2174\/1381612811319370002","article-title":"Mechanisms for targeted delivery of nanoparticles in cancer","volume":"19","author":"Beech","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0235","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1226338","article-title":"Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities","volume":"338","author":"Cheng","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0240","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1073\/pnas.0711714105","article-title":"Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers","volume":"105","author":"Gu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nano.2012.05.015","article-title":"Effect of ligand density, receptor density, and nanoparticle size on cell targeting","volume":"9","author":"Elias","year":"2013","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0250","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jps.22342","article-title":"Controlling ligand surface density optimizes nanoparticle binding to ICAM-1","volume":"100","author":"Fakhari","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0255","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1039\/c2ra01168a","article-title":"Ligand density and clustering effects on endocytosis of folate modified nanoparticles","volume":"2","author":"Moradi","year":"2012","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0260","series-title":"Heterogeneity of Cancers and Its Implication for Targeted Drug Delivery","first-page":"337","article-title":"Cancer targeted drug delivery","author":"Denison","year":"2013"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0265","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0270","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0275","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1038\/ncomms2766","article-title":"Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis","volume":"4","author":"Jung","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0280","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Jamal-Hanjani","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0285","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0295","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nature08989","article-title":"Genome remodelling in a basal-like breast cancer metastasis and xenograft","volume":"464","author":"Ding","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0300","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1084\/jem.154.6.1764","article-title":"Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens","volume":"154","author":"Albino","year":"1981","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0305","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14656566.2011.537260","article-title":"Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature","volume":"15","author":"Arslan","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0320","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00280-011-1791-9","article-title":"Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer","volume":"69","author":"Jakobsen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1349-7006.2008.00782.x","article-title":"Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib","volume":"99","author":"Taniguchi","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0330","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.03.018","article-title":"Molecular portraits of intratumoral heterogeneity in human ovarian cancer","volume":"307","author":"Choi","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0335","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0340","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/nn100213v","article-title":"Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots","volume":"4","author":"Liu","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0350","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1126\/scitranslmed.3003854","article-title":"Intratumor heterogeneity: seeing the wood for the trees","volume":"4","author":"Yap","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0355","first-page":"44","article-title":"Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry","volume":"1","author":"van de Watering","year":"2014","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/cbr.2010.0759","article-title":"Pretargeted radioimmunotherapy for hematologic and other malignancies","volume":"25","author":"Walter","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0365","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7150\/thno.3582","article-title":"Pretargeted molecular imaging and radioimmunotherapy","volume":"2","author":"Goldenberg","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0370","doi-asserted-by":"crossref","first-page":"5598s","DOI":"10.1158\/1078-0432.CCR-07-1223","article-title":"Pretargeted radioimmunotherapy for B-cell lymphomas","volume":"13","author":"Green","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0375","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2002-03-0874","article-title":"Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas","volume":"101","author":"Pagel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0380","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-03-210344","article-title":"Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates","volume":"114","author":"Green","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/0008-5472.CAN-08-2513","article-title":"Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia","volume":"69","author":"Pagel","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0390","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2011-04-347039","article-title":"Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model","volume":"118","author":"Pagel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0395","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1182\/blood-2008-11-187401","article-title":"A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations","volume":"113","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0400","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.1158\/0008-5472.CAN-07-0080","article-title":"Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas","volume":"67","author":"Pagel","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0405","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","article-title":"A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies","volume":"74","author":"Green","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0410","first-page":"437","article-title":"Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts","volume":"44","author":"Subbiah","year":"2003","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0415","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1073\/pnas.0437788100","article-title":"Pretarget radiotherapy with an anti-CD25 antibody\u2013streptavidin fusion protein was effective in therapy of leukemia\/lymphoma xenografts","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0420","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1073\/pnas.97.4.1802","article-title":"Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity","volume":"97","author":"Axworthy","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0425","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2003-09-3284","article-title":"Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"104","author":"Forero","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0430","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/cbr.2000.15.15","article-title":"Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I\/II study results","volume":"15","author":"Weiden","year":"2000","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(01)00133-0","article-title":"Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL)","volume":"40","author":"Weiden","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0440","first-page":"3190s","article-title":"Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I\/II clinical trial","volume":"5","author":"Kraeber-Bodere","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0445","first-page":"3183s","article-title":"Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab\u2032)2 and pretargeted bivalent hapten and evaluation of repeated injections","volume":"5","author":"Kraeber-Bodere","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0450","first-page":"247","article-title":"Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial","volume":"47","author":"Kraeber-Bodere","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0455","series-title":"Cancer Facts & Figures","author":"Society","year":"2015"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0460","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0465","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1593\/neo.07787","article-title":"In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies","volume":"9","author":"Koyama","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0470","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1158\/1078-0432.CCR-07-1119","article-title":"In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies","volume":"13","author":"Barrett","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0475","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nnano.2010.148","article-title":"Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection","volume":"5","author":"Haun","year":"2010","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0480","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/anie.201104389","article-title":"Bioorthogonal reaction pairs enable simultaneous, selective, multi-target imaging","volume":"51","author":"Karver","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0485","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00259-014-2738-2","article-title":"Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts: targeted polymer drug conjugates for cancer diagnosis and therapy","volume":"41","author":"Khaw","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0490","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/316265a0","article-title":"Antibodies against metal chelates","volume":"316","author":"Reardan","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0495","first-page":"226","article-title":"Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens","volume":"29","author":"Goodwin","year":"1988","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0500","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/bc0200172","article-title":"Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen","volume":"13","author":"Karacay","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0505","first-page":"495","article-title":"Pretargeting with bispecific anti-renal cell carcinoma\u00d7anti-DTPA(in) antibody in 3 RCC models","volume":"46","author":"van Schaijk","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0510","first-page":"146","article-title":"Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies","volume":"42","author":"Gestin","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0515","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/bc9901090","article-title":"Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens","volume":"11","author":"Hillairet de Boisferon","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0520","first-page":"1678","article-title":"Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide","volume":"47","author":"McBride","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0525","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bjc.1990.115","article-title":"A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate\u2013carrier conjugate","volume":"61","author":"Pimm","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0530","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-013-1548-4","article-title":"Bispecific Her2\u00d7cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts","volume":"140","author":"Yoon","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0535","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13346-011-0055-x","article-title":"Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy","volume":"2","author":"Gada","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0540","first-page":"1358","article-title":"In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate","volume":"30","author":"Le Doussal","year":"1989","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0545","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/bc970083h","article-title":"Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy","volume":"8","author":"Janevik-Ivanovska","year":"1997","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0550","first-page":"4400","article-title":"Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate","volume":"59","author":"Boerman","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0555","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/17425241003677749","article-title":"Avidin\u2013biotin technology in targeted therapy","volume":"7","author":"Lesch","year":"2010","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0560","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/00006231-198811000-00010","article-title":"Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody","volume":"9","author":"Pimm","year":"1988","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0565","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.nucmedbio.2009.04.010","article-title":"Bifunctional phage-based pretargeted imaging of human prostate carcinoma","volume":"36","author":"Newton-Northup","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0570","first-page":"406","article-title":"Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody\/streptavidin in patients with metastatic colon cancer","volume":"6","author":"Knox","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0575","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-05-3443","article-title":"A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0580","first-page":"867","article-title":"Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2","volume":"45","author":"Cheung","year":"2004","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0585","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2005-11-4327","article-title":"Comparison of a tetravalent single-chain antibody\u2013streptavidin fusion protein and an antibody\u2013streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas","volume":"108","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0590","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/mt.2008.129","article-title":"Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase","volume":"16","author":"Stachler","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0595","first-page":"1791","article-title":"Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication","volume":"31","author":"Kalofonos","year":"1990","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0600","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pro.2203","article-title":"Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin","volume":"22","author":"Yumura","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0605","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1110\/ps.19901","article-title":"Reduced antibody response to streptavidin through site-directed mutagenesis","volume":"10","author":"Meyer","year":"2001","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0610","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0969-8051(97)00061-9","article-title":"Effect of endogenous biotin on the applications of streptavidin and biotin in mice","volume":"24","author":"Rusckowski","year":"1997","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0615","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/bc034049g","article-title":"Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma","volume":"16","author":"Hamblett","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0620","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/bc100030q","article-title":"Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants","volume":"21","author":"Wilbur","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0625","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/bc300567a","article-title":"Tumor-targeting antibody\u2013anticalin fusion proteins for in vivo pretargeting applications","volume":"24","author":"Steiner","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0630","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1039\/C4CC10265G","article-title":"Development of an enzymatic pretargeting strategy for dual-modality imaging","volume":"51","author":"Knight","year":"2015","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0635","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1021\/bc200366t","article-title":"90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy","volume":"22","author":"Liu","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0640","first-page":"333","article-title":"Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector","volume":"54","author":"Liu","year":"2010","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0645","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00006231-200306000-00013","article-title":"Investigations of 99mTc morpholino pretargeting in mice","volume":"24","author":"Liu","year":"2003","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0650","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00259-005-1853-5","article-title":"Further investigations of morpholino pretargeting in mice\u2014establishing quantitative relations in tumor","volume":"32","author":"Liu","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0655","first-page":"1087","article-title":"Amplification targeting: a modified pretargeting approach with potential for signal amplification\u2014proof of a concept","volume":"45","author":"He","year":"2004","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0660","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.10.114","article-title":"Cancer radioimmunotherapy","volume":"3","author":"Sharkey","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0665","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/mp9002909","article-title":"Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF","volume":"7","author":"He","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0670","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1039\/c3ob40897c","article-title":"Bioorthogonal chemistry for pre-targeted molecular imaging\u2014progress and prospects","volume":"11","author":"Carroll","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0675","first-page":"96","article-title":"Bioorthogonal chemistry: implications for pretargeted nuclear (PET\/SPECT) imaging and therapy","volume":"4","author":"Knight","year":"2014","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0680","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1002\/anie.200906294","article-title":"Invivo chemistry for pretargeted tumor imaging in live mice","volume":"49","author":"Rossin","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0685","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1021\/mp500275a","article-title":"Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels\u2013Alder reaction","volume":"11","author":"Rossin","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0690","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2967\/jnumed.112.115840","article-title":"A pretargeted PET imaging strategy based on bioorthogonal Diels\u2013Alder click chemistry","volume":"54","author":"Zeglis","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0695","doi-asserted-by":"crossref","first-page":"10549","DOI":"10.1002\/anie.201304026","article-title":"Mesoporous silica nanoparticle pretargeting for PET imaging based on a rapid bioorthogonal reaction in a living body","volume":"52","author":"Lee","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0700","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1039\/C005154C","article-title":"A pretargeted nanoparticle system for tumor cell labeling","volume":"7","author":"Gunn","year":"2011","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0705","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/nn4053827","article-title":"Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis","volume":"8","author":"Chu","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0710","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/bc050137k","article-title":"Biodegradable nanoparticles for direct or two-step tumor immunotargeting","volume":"17","author":"Nobs","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0715","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2013.06.017","article-title":"Functionalized nanospheres for targeted delivery of paclitaxel","volume":"171","author":"Bushman","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0720","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2008.04.018","article-title":"Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin\u2013biotin technology: formulation development and in vitro anticancer activity","volume":"70","author":"Pulkkinen","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0725","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00689191","article-title":"A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo","volume":"36","author":"Longman","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0730","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.24798","article-title":"In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-l-lysine as effector molecule","volume":"116","author":"Frost","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0735","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/10611860008997904","article-title":"Bispecific MAb aided liposomal drug delivery","volume":"8","author":"Cao","year":"2000","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0740","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nnano.2013.190","article-title":"Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery","volume":"8","author":"Mulvey","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0745","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/bc500605g","article-title":"Enhancing reactivity for bioorthogonal pretargeting by unmasking antibody-conjugated trans-cyclooctenes","volume":"26","author":"Rahim","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0750","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2217\/imt.13.34","article-title":"General overview of radioimmunotherapy of solid tumors","volume":"5","author":"Navarro-Teulon","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0755","first-page":"1201","article-title":"Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv\u2013streptavidin fusion protein","volume":"46","author":"Sato","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0760","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.107.046185","article-title":"Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting","volume":"49","author":"Goldenberg","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0765","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1158\/0008-5472.CAN-08-0037","article-title":"Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody","volume":"68","author":"Sharkey","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0770","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.81.9.2843","article-title":"Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection","volume":"81","author":"Sharkey","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0775","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00259-005-1811-2","article-title":"Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody","volume":"32","author":"Miralli\u00e9","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0780","first-page":"131","article-title":"Clinical optimization of pretargeted radioimmunotherapy with antibody\u2013streptavidin conjugate and 90Y-DOTA-biotin","volume":"41","author":"Breitz","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0785","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/cbr.2010.0800","article-title":"Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted","volume":"25","author":"Liu","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0790","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"Paganelli","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0795","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bjc.6600047","article-title":"Pretargeted adjuvant radioimmunotherapy with yttrium-90\u2013biotin in malignant glioma patients: a pilot study","volume":"86","author":"Grana","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0800","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.uct.2007.04.003","article-title":"Cancer imaging and therapy with bispecific antibody pretargeting","volume":"2","author":"Goldenberg","year":"2007","journal-title":"Update Cancer Ther."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0805","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.critrevonc.2014.03.002","article-title":"Personalized medicine: present and future of breast cancer management","volume":"91","author":"Sabatier","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0810","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1182\/blood-2006-11-056895","article-title":"Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas","volume":"109","author":"Pantelias","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.040_bb0815","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.09.040_bb0820","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tibtech.2007.05.001","article-title":"Engineering antibodies for clinical applications","volume":"25","author":"Jain","year":"2007","journal-title":"Trends Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T14:59:29Z","timestamp":1572533969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915301401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":164,"alternative-id":["S0168365915301401"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.040","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}